Gilead Sciences, Inc.: stock overview

GILDNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$168.08

November 13, 2026Market cap $209B

DCF calculator

What Ploutos Investor adds for Gilead Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Gilead Sciences had revenue of $31.0B over the last 12 months and a net loss of $3.9B. Revenue grew by 3.6% a year on average over the last 5 years. It has net debt of $19.8B. It pays a dividend yielding 1.93%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$209B
1.24B shares
P/E
–
median of 4 years: 18.1
Revenue, 12 months
$31.0B
+3.6% a year over 5 years
Net margin
-12.5%
2025: 28.9%, above 91% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+4.2% a year over 2 years

  • 202510-K
    Revenue$29.4B
  • 202410-K
    Revenue$28.8B
  • 202310-K
    Revenue$27.1B

Fiscal years in figures

GILD's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $115B
$209B
Enterprise value 
$228B
P/E 
–
EV / EBIT 
–
EV / Revenue 
7.4
P/B 3-year median: 6.0
16.0
FCF yield 3-year median: 7.4%
6.6%
Earnings yield 3-year median: 5.5%
–

Profitability

Gross margin 
79.9%
Operating margin 
-7.6%
Net margin 3-year median: 20.9%
-12.5%
ROIC 
-4.3%
ROIC, 5-year average 
12.2%
ROE 
-20.8%

Growth

Revenue, yearly change 
+2.4%
EPS, yearly change 
+1,684.2%
FCF, yearly change 
-8.2%
Revenue, average a year 
+3.6%
EPS, average a year 
+132.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$6.4B
Total debt 
$26.2B
Net debt 
$19.8B
Net debt / EBITDA 
–
Interest cover 
-2.3x
Current ratio 
1.38

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 3.3%
1.93%
Buybacks 
0.92%
Total returned 
2.85%
Shares, yearly change 
-0.3%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

34.0%

Above 94% of the 285 companies in its industry, and 94% of all.

Net margin

28.9%

Above 91% of the 302 companies in its industry, and 90% of all.

ROE

37.5%

Above 92% of the 267 companies in its industry, and 94% of all.

ROA

14.4%

Above 87% of the 313 companies in its industry, and 94% of all.

Revenue growth

2.4%

Above 43% of the 292 companies in its industry, and 36% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
GILEAD SCIENCES, INC.
CIK
882095
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
1.24B

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Gilead Sciences's filings show?

These are Gilead Sciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about GILD

Didn't find what you were looking for?

Ask us
What is GILD's market cap?

Gilead Sciences, Inc.'s market cap is $209B, at a price of $168.08 on November 13, 2026 and 1.24B shares.

How much revenue does GILD have?

Gilead Sciences had revenue of $31.0B over the last 12 months. Over the last 5 years it changed by +3.6% a year on average.

Does GILD pay a dividend?

Yes. Gilead Sciences paid $3.25 per share over the last 12 months, a yield of 1.93% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Gilead Sciences, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.